3 Neil Woodford High-Yield Shares: GlaxoSmithKline plc, Centrica PLC and SSE PLC

GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) and SSE PLC (LON:SSE) are three of the master investor’s high-income picks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskRenowned fund manager Neil Woodford has been thrashing the market for a quarter of a century. Woodford is a very selective stockpicker. Fewer than 1 in 10 of the UK’s top 350 companies earn a place in his funds.

Hence, I always keep an eye on his holdings for promising investment ideas.

The following three FTSE 100 firms all currently offer prospective dividend yields of above 5.5%, compared with the FTSE 100 average of 3.3%:

  Recent share price Forecast yield
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) 1,417p 5.6%
Centrica (LSE: CNA) (NASDAQOTH: CPYYY) 307p 5.7%
SSE (LSE: SSE) 1,438 6.2%

GlaxoSmithKline

GSK’s shares are trading close to a 52-week low. Allegations of bribery in China, which have hurt sentiment, were already in the public domain when Woodford loaded up on GSK stock for his new fund towards the end of June.

However, the UK’s top pharma company has since released disappointing half-year results, with competition from generic drugs, some supply-chain problems and adverse currency movements all playing a part. Core earnings are now expected to be flat for the full year (at constant exchange rates).

Nevertheless, management said “we remain confident in GSK’s medium and long-term growth prospects”. The Board lifted the Q2 dividend (the ex-dividend date is 6 August) by 6%, and analysts’ full-year expectations give a prospective yield of 5.6%.

Centrica

Just as GSK’s China troubles didn’t stop Woodford from investing in the pharma firm, so the political and regulatory headwinds currently buffeting the UK’s energy utilities didn’t stop him backing Centrica, the owner of British Gas. As with GSK, Centrica’s shares are currently trading close to a 52-week low.

Also like GSK, Centrica has recently released disappointing first-half results. Abnormal weather conditions played a big part, and management said full-year earnings will be lower than last year.

However, the company expects a return to growth in 2015 and the Board reaffirmed its “commitment to real dividend growth”. The half-year payout was lifted 4% (ex-dividend date of 24 September), and analysts’ full-year forecasts give a prospective yield of 5.7%.

SSE

SSE faces the same challenging political and regulatory environment as Centrica. But again, Woodford has backed the previously named Scottish & Southern Energy for his new fund.

SSE told shareholders at its AGM last month that despite tough energy market conditions, “we are on course to give shareholders a return on their investment through a dividend increase that at least keeps pace with inflation”.

Analysts are forecasting a rise of 3% or so on last year’s payout, which gives a prospective top-of-the-tree yield of 6.2%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Does a 9.3% yield and a growing dividend make Legal & General shares a passive income no-brainer?

Legal & General shares have been a bad investment over the last five years. But could it be a huge…

Read more »

Charticle

2 brilliant (but very different) shares I want to buy if they get cheaper in 2025!

This contrasting pair of businesses has caught our writer's eye. But he is not ready to buy the shares at…

Read more »

Investing Articles

3 steps to start buying shares with a spare £250

Christopher Ruane explains three simple but important principles he thinks people should consider when they start buying shares, even with…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

FTSE 100 shares: bargain hunting to get richer!

After hitting a new high this year, might the FSTE 100 still offer bargain shares to buy? Our writer thinks…

Read more »

Investing Articles

How to try and turn a £50K SIPP into a £250K retirement fund

Christopher Ruane explains how a long-term approach and careful share selection could potentially help an investor quintuple the value of…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

My £3 a day passive income plan for 2025

Christopher Ruane walks through his plan for next year and beyond of squirreling away and investing a few pounds a…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Can the FTSE 250’s Raspberry Pi boost my portfolio over the next decade?

This British technology stock in the FTSE 250 has exploded onto the London stock market and right now its future…

Read more »

Investing Articles

Does acquiring Direct Line make Aviva shares a buy?

A big acquisition should give Aviva greater scale and profitability, increasing the value of its shares. But is it an…

Read more »